Clinical Trial Update: A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating emibetuzumab in combination with ramucirumab in various advanced cancers, with completed status and results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Ramucirumab (ramucirumab)
• emibetuzumab (emibetuzumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Advanced Cancer, Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-19